Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells

Emerson C. Perin, Michael Murphy, John P. Cooke, Lem Moyé, Timothy D. Henry, Judy Bettencourt, Amir Gahremanpour, Nicholas Leeper, R. David Anderson, William R. Hiatt, Joao A. Lima, Bharath Venkatesh, Shelly L. Sayre, Rachel W. Vojvodic, Doris A. Taylor, Ray F. Ebert, Alan T. Hirsch

Research output: Contribution to journalArticle

Abstract

Peripheral artery disease (PAD) is recognized as a public health issue because of its prevalence, functional limitations, and increased risk of systemic ischemic events. Current treatments for claudication, the primary symptom in patients with PAD, have limitations. Cells identified using cytosolic enzyme aldehyde dehydrogenase (ALDH) may benefit patients with severe PAD but has not been studied in patients with claudication. PACE is a randomized, double-blind, placebo-controlled clinical trial conducted by the Cardiovascular Cell Therapy Research Network to assess the safety and efficacy of autologous bone marrow-derived ALDHbr cells delivered by direct intramuscular injections in 80 patients with symptom-limiting intermittent claudication. Eligible patients will have a significant stenosis or occlusion of infrainguinal arteries and a resting ankle-brachial index less than 0.90 and will be randomized 1:1 to cell or placebo treatment with a 1-year follow-up. The primary end points are the change in peak walking time and leg collateral arterial anatomy, calf muscle blood flow, and tissue perfusion as determined by magnetic resonance imaging at 6 months compared with baseline. The latter 3 measurements are new physiologic lower extremity tissue perfusion and PAD imaging-based end points that may help to quantify the biologic and mechanistic effects of cell therapy. This trial will collect important mechanistic and clinical information on the safety and efficacy of ALDHbr cells in patients with claudication and provide valuable insight into the utility of advanced magnetic resonance imaging end points.

Original languageEnglish (US)
Pages (from-to)667-673.e2
JournalAmerican heart journal
Volume168
Issue number5
DOIs
StatePublished - Nov 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Perin, E. C., Murphy, M., Cooke, J. P., Moyé, L., Henry, T. D., Bettencourt, J., Gahremanpour, A., Leeper, N., Anderson, R. D., Hiatt, W. R., Lima, J. A., Venkatesh, B., Sayre, S. L., Vojvodic, R. W., Taylor, D. A., Ebert, R. F., & Hirsch, A. T. (2014). Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells. American heart journal, 168(5), 667-673.e2. https://doi.org/10.1016/j.ahj.2014.07.021